A company update on financing that outlines plans to advance a radiotherapeutics drug development pipeline and expand manufacturing capacity.
Key Takeaways
- Jul 31, 2026, 08:00 ET Share this article Round brings total capital raised to over $240 Million
- Financing included strong participation from existing investors Duquesne Family Office and Bristol Myers Squibb
- Proceeds from the financing will fuel Ratio's next phase of growth